Features
<b><i>Social Media Scene:</i></b> How Social Media Has Changed PR and Corporate Communications at Law Firms
Technology has become a disruptive force in the legal industry and in the way legal services are delivered. Perhaps no technology has had a larger impact in the way law firms communicate with their clients and prospects than social media.
Features
Coaching: A Shift in Law Firm Culture
Like other firms, Seyfarth found that developing employees, increasing engagement, addressing generational changes, and matching associate objectives with firm goals is a constant challenge. Here's how they solved the problem.
Features
Word 2013: Better by Design
The good work we did to set up the default look and feel of the Microsoft Word environment can have a huge impact on the usability of the product. Another way that we can improve the overall experience is to tweak the variety of settings that lurk behind the scenes. That's right, it is time to talk about Word Options.
Features
<b><i>At the Intersection:</i></b> Taking the Plunge
So you're thinking about diving into the election for Managing Partner? Before you throw your hat into the firm's MP selection process, now is the time to pause and reflect on your motivations and incentives for what is bound to be a significant shift in role, responsibility, stature, and quality of life for at least a few years.
Features
<b><i>Sales Speak:</i></b> Asking for Business
Given the reality that law schools, for the most part, do not adequately prepare lawyers to engage in the business of law (including sales), it is no wonder why the fear of directly asking for new business is an obstacle for many lawyers.
Features
Levenfeld Pearlstein Makes a Winning Move with Client Extranet Technology
Ask any law firm leader to list their key business strategies and delivering client value will undoubtedly top the list. Talking about innovation is fine and well, but is not worth much unless your firm is willing to make strategic changes, some of which might hurt in the short term, in order to open the door to new ideas and a client-centric approach.
Features
The Tax Increase Prevention Act of 2014
On Dec. 19, 2014, the President signed into law the long-awaited year-end tax package, the Tax Increase Prevention Act of 2014 (TIPA). This law extended to the end of 2014 many but not all of the individual, business, and energy provisions that expired at the end of 2013. In addition, the law provides for a new tax-advantaged savings program to aide in meeting the financial needs of disabled individuals, called the " Achieving a Better Life Experience" (ABLE) program.
Features
Pricing It Right: Restructuring Billing
As pressure on pricing continues, Big Law firms are buying (or building) analytics technology and hiring pricing specialists ' people who use market data, internal firm data and economics/pricing experience to ensure that firms are smart about bidding on work. The mission: Educate clients about the value the firm brings, while making sure to charge enough to make a profit.
Features
Note from Your Editor
As our world continues to "dance as fast as it can," legal marketers around the globe continue to struggle with educating their lawyers in the ways of the "new normal."
Columns & Departments
In the Marketplace
Who's doing what; who's going where.
Need Help?
- Prefer an IP authenticated environment? Request a transition or call 800-756-8993.
- Need other assistance? email Customer Service or call 1-877-256-2472.
MOST POPULAR STORIES
- Surveys in Patent Infringement Litigation: The Next FrontierMost experienced intellectual property attorneys understand the significant role surveys play in trademark infringement and other Lanham Act cases, but relatively few are likely to have considered the use of such research in patent infringement matters. That could soon change in light of the recent admission of a survey into evidence in <i>Applera Corporation, et al. v. MJ Research, Inc., et al.</i>, No. 3:98cv1201 (D. Conn. Aug. 26, 2005). The survey evidence, which showed that 96% of the defendant's customers used its products to perform a patented process, was admitted as evidence in support of a claim of inducement to infringe. The court admitted the survey into evidence over various objections by the defendant, who had argued that the inducement claim could not be proven without the survey.Read More ›
- Use of Deferred Prosecution Agreements In White Collar InvestigationsThis article discusses the practical and policy reasons for the use of DPAs and NPAs in white-collar criminal investigations, and considers the NDAA's new reporting provision and its relationship with other efforts to enhance transparency in DOJ decision-making.Read More ›
- The DOJ's New Parameters for Evaluating Corporate Compliance ProgramsThe parameters set forth in the DOJ's memorandum have implications not only for the government's evaluation of compliance programs in the context of criminal charging decisions, but also for how defense counsel structure their conference-room advocacy seeking declinations or lesser sanctions in both criminal and civil investigations.Read More ›
- The DOJ's Corporate Enforcement Policy: One Year LaterThe DOJ's Criminal Division issued three declinations since the issuance of the revised CEP a year ago. Review of these cases gives insight into DOJ's implementation of the new policy in practice.Read More ›
- In the SpotlightOn May 9, 2003, the U.S. Attorney's Office for the District of Massachusetts announced that Bayer Corporation, the pharmaceutical manufacturer, had been sentenced and ordered to pay a criminal fine of $5,590,800 stemming from its earlier plea of guilty to violating the Federal Prescription Drug Marketing Act by failing to list with the FDA its drug product, Cipro, that was privately labeled for an HMO. Such listing is required under the federal Food, Drug & Cosmetic Act. The Federal Prescription Drug Marketing Act, Pub. L. 100-293, enacted on April 22, 1988, as modified on August 26, 1992 by the Prescription Drug Amendments (PDA) Pub. L. 102-353, 106 Stat. 941, amended sections 301, 303, 503, and 801 of the Federal Food, Drug, and Cosmetic Act, codified at 21 U.S.C. '' 331, 333, 353, 381, to establish requirements for distributing prescription drug samples.Read More ›
